Martin Körbling
Körbling, Martin
VIAF ID: 198144782966437622361 (Personal)
Permalink: http://viaf.org/viaf/198144782966437622361
Preferred Forms
-
100 1 _
‡a
Körbling, Martin
-
100 0 _
‡a
Martin Körbling
4xx's: Alternate Name Forms (2)
5xx's: Related Names (1)
Works
| Title | Sources |
|---|---|
| BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD |
|
| Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas |
|
| Cord-blood engraftment with ex vivo mesenchymal-cell coculture |
|
| Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. |
|
| Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units |
|
| Effect of non-permissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T cell depletion |
|
| Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia |
|
| High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma |
|
| High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation |
|
| Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma |
|
| Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma |
|
| Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival |
|
| Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. |
|
| Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. |
|
| Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. |
|
| Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation |
|
| Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma |
|
| A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas |
|
| Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation |
|
| Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment |
|
| Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization |
|
| Vergleichende Untersuchungen über muskulär angreifende Antihypertensiva an der wachen und narkotisierten Ratte |
|
